Drugs

A CADTH review looks into the evidence amid increased interest in using ketamine to treat mental illnesses.

Rimegepant is the second oral “gepant” for acute migraine to be marketed in Canada following ubrogepant (Ubrelvy).

A review of new launches, new indications, new dosage forms and Health Canada advisories.

The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?

The advent of long-acting antiretroviral therapies for HIV suppression and prevention.

The rest of the supplies will expire on May 31.

Already used to treat symptoms, abatacept could be used earlier.

With its reduced injection frequency, insulin icodec (Awiqli) has the potential to provide better adherence and greater treatment satisfaction in some patients.